SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (OTCQB: MNTR) announced it has taken a $1.0 million position in the stock of GW Pharmaceuticals, Plc (NASDAQ: GWPH), a United Kingdom based group developing a portfolio of cannabinoid prescription medicines. Mentor Capital, Inc. CEO, Chet Billingsley explains his investment analysis, “During the last few months Mentor has seen a rapid and continuing expansion in investable cash and we wanted to get more of that working for us in the also rapidly growing medical marijuana sector in a general up market for stocks. GW Pharma is somewhat isolated from the political uncertainty in much of the domestic cannabis market because it is both medically focused while internationally based and marketed.”
Mentor reports that it held $2.5 million in cash prior to this week’s GW Pharmaceutical stock purchase and its 7,500 shareholders held an additional $11 million in long-term warrants that have been the ongoing source of its investment cash. Mentor’s preferred involvement is with larger and private pre-IPO medical marijuana companies that Mentor can help operationally prepare for the public market and finance, sometimes working with institutional partners seeking public liquidity. As such, Mentor is not an Investment Company under the 1940 Act.
About Mentor Capital: The Company seeks to come alongside and assist private medical marijuana and cannabis companies and their founders in meeting their liquidity and financial objectives, to add protection for investors and to help incubate private cannabis companies. Additional important information for investors is presented at: www.MentorCapital.com.
This press release is neither an offer to sell, nor a solicitation of offers to purchase, securities.
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the federal securities laws, including statements concerning financial projections, financing activities, corporate combinations, product development activities and sales and licensing activities. Such forward-looking statements are not guarantees of future results or performance, are sometimes identified by words of condition such as “should,” “could,” “expects,” “may,” “intends,” “seeks,” “looks,” “moves,” or “plans” and are subject to a number of risks and uncertainties, known and unknown, that could cause actual results to differ materially from those intended or anticipated. Such risks include, without limitation: nonperformance of investments, partner and portfolio difficulties, potential delays in marketing and sales, problems securing the necessary financing to continue operations, problems involving continued illegality of cannabis products, potential of competitive products, services, and technologies, difficulties experienced in product development, in recruiting knowledgeable personnel, in collecting judgments and in protecting intellectual property. Further information concerning these and other risks is included in the Company’s Form 10-K and 10-Q filings which, along with other very important information about the Company, can be found here:
The Company undertakes no obligation to update or revise such forward-looking statements to reflect new information, events or circumstances occurring after the date of this press release.